Search by Drug Name or NDC
NDC 00054-0407-13 Ritonavir 100 mg/1 Details
Ritonavir 100 mg/1
Ritonavir is a ORAL TABLET, FILM COATED in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by West-Ward Pharmaceuticals Corp.. The primary component is RITONAVIR.
MedlinePlus Drug Summary
Ritonavir is used along with other medications to treat human immunodeficiency virus (HIV) infection. Ritonavir is in a class of medications called protease inhibitors. It works by decreasing the amount of HIV in the blood. Although ritonavir does not cure HIV, it may decrease your chance of developing acquired immunodeficiency syndrome (AIDS) and HIV-related illnesses such as serious infections or cancer. Taking these medications along with practicing safer sex and making other lifestyle changes may decrease the risk of transmitting the HIV virus to other people.
Related Packages: 00054-0407-13Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Ritonavir
Product Information
| NDC | 00054-0407 |
|---|---|
| Product ID | 0054-0407_e167f497-2f1b-42f7-b807-a3a117385238 |
| Associated GPIs | 12104560000320 |
| GCN Sequence Number | 066047 |
| GCN Sequence Number Description | ritonavir TABLET 100 MG ORAL |
| HIC3 | W5C |
| HIC3 Description | ANTIVIRALS, HIV-SPECIFIC, PROTEASE INHIBITORS |
| GCN | 28224 |
| HICL Sequence Number | 010412 |
| HICL Sequence Number Description | RITONAVIR |
| Brand/Generic | Generic |
| Proprietary Name | Ritonavir |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | Ritonavir |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | TABLET, FILM COATED |
| Route | ORAL |
| Active Ingredient Strength | 100 |
| Active Ingredient Units | mg/1 |
| Substance Name | RITONAVIR |
| Labeler Name | West-Ward Pharmaceuticals Corp. |
| Pharmaceutical Class | Breast Cancer Resistance Protein Inhibitors [MoA], Cytochrome P450 1A2 Inducers [MoA], Cytochrome P450 2B6 Inducers [MoA], Cytochrome P450 2C19 Inducers [MoA], Cytochrome P450 2C9 Inducers [MoA], Cytochrome P450 2D6 Inhibitors [MoA], Cytochrome P450 3A In |
| DEA Schedule | n/a |
| Marketing Category | ANDA |
| Application Number | ANDA202573 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 00054-0407-13 (00054040713)
| NDC Package Code | 0054-0407-13 |
|---|---|
| Billing NDC | 00054040713 |
| Package | 30 TABLET, FILM COATED in 1 BOTTLE (0054-0407-13) |
| Marketing Start Date | 2018-03-20 |
| NDC Exclude Flag | N |
| Pricing Information | |
| Price Per Unit | 1.05096 |
| Pricing Unit | EA |
| Effective Date | 2024-02-21 |
| NDC Description | RITONAVIR 100 MG TABLET |
| Pharmacy Type Indicator | C/I |
| OTC | N |
| Explanation Code | 1 |
| Classification for Rate Setting | G |
| As of Date | 2024-02-21 |